Resources

Publications

12/10/2023
- Oncology
ESR1 Mutations Drive Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer
SABCS 2023
12/08/2023
- Oncology
RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer
JCO Precision Oncology
12/04/2023
- Oncology
Real-World Evaluation of Racial and Socioeconomic Disparities in Patients With NSCLC Treated With Immunotherapy
IASLC NACLC 2023
12/01/2023
- Oncology
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Clinical Cancer Research
12/01/2023
- Oncology
Radiogenomics For EGFR Mutation Status Prediction in CT Images: Impact Of Model Design on Performance and Prospective Generalizability
RSNA 2023
11/09/2023
- Oncology
MAP2K1-Mutated Melanocytic Tumors Have Reproducible Histopathologic Features and Share Similarities With Melanocytic Tumors With BRAF V600E Mutations
Journal of Cutaneous Pathology
11/04/2023
- Oncology
Genomic Characterization of Chondrosarcoma: A Rare Sarcoma With Clinical Responses to Immune Checkpoint Inhibition
CTOS 2023
11/03/2023
- Oncology
EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
SITC 2023
11/03/2023
- Oncology
BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
SITC 2023
11/03/2023
- Oncology
Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy
SITC 2023

26 27 28